Ardelyx Inc (ARDX)
7.775
-0.30
(-3.66%)
USD |
NASDAQ |
May 10, 16:00
7.77
0.00 (0.00%)
After-Hours: 20:00
Ardelyx Cash from Financing (TTM): 148.35M for March 31, 2024
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 148.35M |
December 31, 2023 | 146.30M |
September 30, 2023 | 139.09M |
June 30, 2023 | 115.70M |
March 31, 2023 | 126.32M |
December 31, 2022 | 75.34M |
September 30, 2022 | 71.07M |
June 30, 2022 | 41.59M |
March 31, 2022 | 48.17M |
December 31, 2021 | 83.00M |
September 30, 2021 | 89.67M |
June 30, 2021 | 85.47M |
March 31, 2021 | 56.96M |
December 31, 2020 | 22.78M |
September 30, 2020 | 156.65M |
June 30, 2020 | 156.07M |
March 31, 2020 | 155.87M |
December 31, 2019 | 155.48M |
September 30, 2019 | 0.417M |
June 30, 2019 | 0.395M |
March 31, 2019 | 103.45M |
Date | Value |
---|---|
December 31, 2018 | 103.55M |
September 30, 2018 | 103.56M |
June 30, 2018 | 103.62M |
March 31, 2018 | 0.578M |
December 31, 2017 | 0.685M |
September 30, 2017 | 0.889M |
June 30, 2017 | 110.32M |
March 31, 2017 | 110.49M |
December 31, 2016 | 191.20M |
September 30, 2016 | 191.00M |
June 30, 2016 | 81.32M |
March 31, 2016 | 155.84M |
December 31, 2015 | 75.01M |
September 30, 2015 | 75.06M |
June 30, 2015 | 75.07M |
March 31, 2015 | 61.61M |
December 31, 2014 | 61.31M |
September 30, 2014 | 61.24M |
June 30, 2014 | 61.24M |
March 31, 2014 | -0.001M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
0.395M
Minimum
Jun 2019
156.65M
Maximum
Sep 2020
93.73M
Average
87.57M
Median
Cash from Financing (TTM) Benchmarks
Nektar Therapeutics | 0.03M |
Rigel Pharmaceuticals Inc | 18.37M |
Omeros Corp | -106.08M |
Vistagen Therapeutics Inc | 128.17M |
Karyopharm Therapeutics Inc | 1.124M |